Search results
Showing 406 to 420 of 1346 results for long term conditions
Evidence-based recommendations on using coronary artery stents in adults.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Balloon dilation for chronic eustachian tube dysfunction (HTG534)
Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.
View recommendations for HTG534Show all sections
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.
View recommendations for HTG549Show all sections
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.
Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder (HTG645)
Evidence-based recommendations on extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. This involves placing a device on the skin that delivers short pulses of sound into the shoulder. The aim is to reduce pain and improve shoulder function.
View recommendations for HTG645Show all sections
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
Epithelial radiofrequency ablation for Barrett's oesophagus (HTG219)
Evidence-based recommendations on epithelial radiofrequency ablation for Barrett's oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy cells.
View recommendations for HTG219Show all sections
Sections for HTG219
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.